Literature DB >> 27892980

Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors.

Robert M J Purbrick1, Olaoluwakitan A Osunkunle2, Denis C Talbot3, Susan M Downes2.   

Abstract

Entities:  

Year:  2017        PMID： 27892980     DOI： 10.1001/jamaoncol.2016.4213

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti
Journal:  Ophthalmology       Date:  2017-07-12       Impact factor: 12.079

2.  Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition.

Authors:  William Foulsham; Benjeil Z Edghill; O D Julia Canestraro; Vicky Makker; Jason Konner; David H Abramson; Jasmine H Francis
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-08

3.  MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants.

Authors:  Jasmine H Francis; Eli L Diamond; Ping Chi; Korey Jaben; David M Hyman; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2019-10-21

4.  Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Authors:  Mathilde Berger; Mona Amini-Adlé; Delphine Maucort-Boulch; Philip Robinson; Luc Thomas; Stéphane Dalle; Pierre-Yves Courand
Journal:  Cancer Med       Date:  2020-02-14       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.